Last reviewed · How we verify
Atypical hemolytic uremic syndrome
Approved treatments
- H5G1.1 · AstraZeneca
Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation. - Soliris · Apellis Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Atypical hemolytic uremic syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Atypical hemolytic uremic syndrome treatment landscape brief
- Atypical hemolytic uremic syndrome treatment updates RSS
Frequently asked questions about Atypical hemolytic uremic syndrome
What drugs treat Atypical hemolytic uremic syndrome?
Tracked treatments include H5G1.1, Soliris.
What is the treatment for Atypical hemolytic uremic syndrome?
Standard treatment for Atypical hemolytic uremic syndrome includes H5G1.1, Soliris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Atypical hemolytic uremic syndrome patent cliff · Atypical hemolytic uremic syndrome CI report
- Treatment: H5G1.1 · AstraZeneca
- Treatment: Soliris · Apellis Pharmaceuticals, Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing